Oral Kavite Skuamoz Hücreli Karsinom Hastalarında Pdl 1’i N Histopatolojik Korelasyonu ve Prognoza Etkisi
Özet
Oral cavity
malignancies are highly morbid and mortal, with more than 90% consisting of squamous
cell carcinomas SCC). PD L1 protein, found on the membrane of tumor cells, binds to T
lymphocytes and inactivates them. PD L1 expression has been shown to be associated
with survival in many malignancies, especially malignant melanoma, colorectal
carcinoma and lung cancer The aim of our study is to evaluate the relationship of PD L1
expression with patient characteristics and survival outcomes in oral cavity SCCs. For this
purpose, adult patients diagnosed with oral cavity SCC who applied to Hacettepe
University Faculty o f Medicine, Department of Otorhinolaryngology between 2014 and
2022 were included in the study. Baseline demographic and clinical data of the patients
were examined retrospectively. Paraffin blocks containing the primary tumor and lymph
node metastases in the pathology archive were evaluated by immunohistochemistry for
PD L1 expression, and tumor proportion score ( and combined positive score (
were obtained. Possible relationships between TPS and CPS and patient characteristics
and survival outcome s were investigated using statistical methods. The mean age of a total
of 96 patients included in the study ( male and 38.5% female) was 58.758.7±15.5 years.
The frequency of CPS 20% in patients diagnosed with lower lip SCC was found to be
significantly higher compared to other localizations ( vs. 60.3%, p 0.015).
Similarly, TPS positivity was associated with lower lip involvement 1%, p=0.014;
20%, p<0.001). In univariate analyses, tongue or lower lip involvement, stage III IV
disease or ECOG PS 2 at diagnosis, receiving chemotherapy or radiotherapy, and 20%
TPS in the primary tumor tissue were associated with progression free survival (
The multivariate regression model showed that ECOG PS 2 was an independent factor
determining the r isk of progression ( 2.206, 95% CI: 1.153 4.219, p=0.017). When
the model was applied to 37 patients who had not received chemotherapy or radiotherapy,
ECOG PS 2 ( 26.39, 95% CI: 4.089 170.4, p<0.001), stage III IV disease at
diagnosis ( 10.57, 9 5% CI: 1.874 59.66, p=0.008) and 20% TPS in primary tumor
tissue ( 0.125, 95% CI: 0.026 0.594, p=0.009) were determined as independent risk
factors for PFS. In conclusion, our study revealed that increased tumoral PD L1
expression is an independent fa ctor that reduces the risk of progression in early stage
patients who have not received chemotherapy or radiotherapy.
Key
